A hospital-based cost minimization study of the potential financial impact on the UK health care system of introduction of iron isomaltoside 1000 by Bhandari, Sunil
© 2011 Bhandari, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Therapeutics and Clinical Risk Management 2011:7 103–113
Therapeutics and Clinical Risk Management Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
103
PeRsPeCTives
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/TCRM.S17536
A hospital-based cost minimization study of the 
potential financial impact on the UK health care 
system of introduction of iron isomaltoside 1000
sunil Bhandari
Department of Renal Medicine,  
Hull and east Yorkshire Hospitals 
National Health service Trust and 
Hull York Medical School, Kingston 
upon Hull, UK
Correspondence: Prof sunil Bhandari 
Department of Renal Medicine,  
Hull and east Yorkshire Hospitals NHs 
Trust and Hull York Medical school, 
Kingston upon Hull, HU32JZ, UK 
Tel +44 148 267 4566 
Fax +44 148 267 4998 
email sunil.bhandari@hey.nhs.uk
Background: The clinical need to be able to administer high doses of intravenous iron 
  conveniently in a single rapid infusion has been addressed by the recent introduction of 
  ferric carboxymaltose and subsequently iron isomaltoside 1000. Neither requires a test dose. 
Ferric carboxymaltose can be administered at 15 mg/kg body weight to a maximum dose of 
1000 mg, whereas iron isomaltoside 1000 can be administered at 20 mg/kg body weight. The 
ability to give high doses of iron is important in the context of managing iron deficiency anemia 
in a number of clinical conditions where demands for iron are high (including chronic blood loss 
  associated with inflammatory bowel disease, menorrhagia, and chronic kidney disease). It is also 
an important component in the strategy as an alternative to a blood transfusion.   Affordability 
is a key issue for health services.
Methods: This study was a comparative analysis of the costs of administering the newly 
  available intravenous iron formulations against standard practice (blood transfusion, intravenous 
iron sucrose) by considering the cost of this treatment option plus nursing costs associated with 
administration, equipment for administration, and patient transportation in the secondary care 
(hospital) setting across three dosage levels (600 mg, 1000 mg, and 1600 mg).
Results and conclusion: The analysis indicates that the use of iron isomaltoside 1000 results 
in a net saving when compared with iron sucrose, blood, and ferric carboxymaltose. At 600 mg 
and 1000 mg doses, it is cheaper than low-molecular-weight iron dextran but more expensive at 
a dose of 1600 mg. However, it takes six hours to administer low-molecular-weight iron dextran 
at this dose level, which is inconvenient and reduces patient throughput (productivity).
Keywords: iron isomaltoside 1000, iron deficiency anemia, high dose, single dose, parenteral 
iron, cost minimization
Introduction
Blood is a declining resource. The safety associated with the receipt of a blood infusion 
has progressively improved over the last decade but there are recognized risks associ-
ated with a blood transfusion.1 Strategies to reduce the risk have led to the imposition 
of restrictions on members of the population that can be donors. This has resulted in 
a decline in the volume of blood donated. Additionally, following the identification 
of blood-borne diseases in blood donated by UK donors (eg, prion-related diseases, 
including Creutzfeldt-Jakob disease), certain cohorts of the population are prevented 
from receiving blood and blood products prepared from blood donated in the UK.
The National Blood Transfusion Service has encouraged the conservation and 
appropriate use of blood and blood products.2 In addition, reducing inappropriate 
blood use policy is aimed at reducing the risk associated with the process of   matching Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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and administering blood in the secondary and tertiary care 
settings.
These developments have been at a time when the impor-
tance, implications, and prevalence of iron deficiency anemia 
is being appreciated and associated with a broad range of 
clinical conditions and situations:
•	 In chronic kidney disease patients with/without erythro-
poietin replacement therapy
•	 In patients undergoing various modes of dialysis therapy
•	 Anemia associated with pregnancy (pre/postpartum, 
  following hemorrhage)
•	 Anemia following “blood-thirsty” surgical procedures 
eliminating or reducing the need for postsurgery 
  transfusion (eg, orthopedics, colorectal surgery)
•	 In surgery associated with the elderly (who are often 
iron-deficient and/or anemic)
•	 Iron deficiency anemia associated with anemia of chronic 
disease
•	 Chronic iron deficiency anemia (often presenting with 
acute symptoms)
•	 Chronic occult blood loss (inflammatory bowel disease)
•	 Anemia associated with cancer or the use of chemothera-
peutic agents
•	 Menorrhagia (heavy uterine bleeding).
Iron increasingly plays a major role in “blood   conservation” 
policies. Thus, in the situations outlined above, iron store 
repletion can result in erythropoiesis, ie, restoring or improv-
ing hemoglobin levels. This can commonly be achieved 
without the need for concomitant   erythropoiesis-stimulating 
therapy.3
Anemia of chronic disease may be a comorbidity of a num-
ber of chronic conditions. In these conditions, where hepcidin 
blocks both the absorption of iron from the gastrointestinal 
tract and release of stored iron, intravenous iron has been 
demonstrated as being able to bypass these blocks and act as 
the substrate for erythropoiesis.4,5 Compared with oral iron, 
intravenous iron repletes iron stores more rapidly, and can be 
given at high doses as a total dose infusion which improves 
compliance. Oral iron is associated with poor   tolerance, poor 
compliance, a high frequency of adverse events, and less rapid 
restoration of iron stores. It is poorly absorbed in patients with 
anemia of chronic disease. As such, its role as a useful source 
of iron supplementation is limited.
The administration of intravenous iron may be considered 
a more physiological method of addressing chronic iron 
deficiency anemia than a blood transfusion. A transfusion 
addresses the acute symptoms of anemia, but is a poor and 
expensive source of iron, whereas intravenous iron provides 
physiologically available iron for both erythropoiesis and 
replenishing iron stores.
The purpose of this paper was to examine the compara-
tive cost to the health care economy of the intravenous iron 
supplementation options, including blood transfusions. 
The economic importance is driven by the need to optimize 
the use of services in the current challenging financial cli-
mate in parallel with serving the needs of patients. In these 
circumstances, value for money and the overall relative cost 
of treatments are important when making policy prescribing 
decisions. Given that all options will achieve similar clinical 
responses, a cost minimization analysis was undertaken to 
determine the least expensive option overall.
Background
Iron is an essential metabolic element. The human body 
requires about 3 g of elemental iron daily. Iron cannot be 
actively excreted. Iron loss is passive. In a healthy individual 
it occurs through the sloughing off of the intestinal entero-
cytes (gut lining). In ill health, blood loss may contribute 
to iron loss (as may the taking of frequent blood samples 
for hematinic studies). The main physiological control 
  mechanism is somewhat complex (Figure 1).
Iron absorption is affected by a number of parameters, 
including iron depletion and is restricted by inflammation. 
The precise mechanism is not fully elucidated, but involves the 
protein, hepcidin, a 25-amino acid synthesized in the liver. Hep-
cidin acts as a regulator of iron metabolism which has important 
effects on iron absorption, transportation, and storage.6 Hepci-
din binds to the iron exporter protein, ferroportin, which causes 
internalization and degradation of iron.7 This interaction leads 
to reduced red cell iron absorption and sequestration in the 
reticuloendothelial system. Stimuli such as hypoxia, as a result 
of anemia, may also inhibit hepcidin, via hypoxia-inducible 
factor, leading to increased iron absorption.
Although iron is essential to life it is also potentially 
toxic. This has affected the ability to prepare safe formu-
lations for intravenous administration. Early intravenous 
formulations were associated with adverse effects, which 
were occasionally severe. With the recent controversies 
involving erythropoiesis-stimulating therapy, there has 
been a renewed desire to develop intravenous iron formula-
tions that can be administered at flexible dosage levels, and 
given at a rate compatible with both patient convenience 
and compliance, and in a timely manner for health care 
professionals.8–10
The introduction of a high-molecular-weight iron dextran 
formulation (no longer available in Europe) was a first step in Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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iron repletion. This was administered slowly over a number 
of hours and was associated with a high frequency of adverse 
events. Iron sucrose and subsequently low-molecular-weight 
iron dextran were introduced in the late 1990s.
Low-molecular-weight iron dextran offers a flexible dose 
regimen, and can be delivered as a 100 mg intramuscular 
injection, as a slow intravenous injection (up to 200 mg 
iron), as an intravenous drip infusion (up to 200 mg), or as a 
total dose infusion (Tables 1, 2 and 3). A total dose infusion 
allows high doses (20 mg/kg) to be administered in a single 
infusion, but over a period of time - normally six hours. A 
test dose is required prior to administration.11
Iron sucrose can be administered in a single bolus 
injection limited to 100 mg, given as a slow injection over 
five minutes or 200 mg over 10 minutes (Table 2). If given 
by infusion, 100 mg is given over 15 minutes and 200 mg 
over 30 minutes (maximum three per week, maximum dose 
600 mg/week) (Table 1).12
In the UK for the past decade, these products have pro-
vided the means to administer iron via the parenteral route, 
albeit with limitations. In 2008, ferric carboxymaltose was 
introduced to the UK. This formulation contains iron in 
its ferric state as a complex with a carbohydrate polymer, 
does not require a test dose, and can be administered as an 
infusion at a dose of 15 mg/kg body weight to a maximum 
of 1000 mg in a single infusion if the patient weighs at 
least 67 kg (Table 1, 2 and 3).13 More recently, iron isomalto-
side 1000 has been approved for marketing in Europe. 
A test dose is not required and doses can be administered 
up to 20 mg/kg to the full body weight.14 Individuals with a 
minimum body weight of 50 kg can receive a 1000 mg dose 
(Tables 1,  2 and 3). This allows more patients to achieve iron 
repletion in a single rapid infusion. This is a nondextran, 
low anaphylactic, nonbranched carbohydrate chain with a 
molecular weight below 1000 Da.14
Methods
The purpose of this study was to examine the cost of admin-
istering iron isomaltoside 1000 and ferric carboxymaltose, 
and to compare these with existing standard treatments. The 
cost of administering iron isomaltoside 1000 and ferric car-
boxymaltose was compared with the cost of administering a 
blood transfusion, iron sucrose, and low-molecular-weight 
iron dextran across a range of doses in a secondary care 
(hospital) setting. The costs included transport (to reflect 
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Figure 1 schematic diagram of the role of hepcidin affecting the movement of iron.* 
Note: *Developed from Gantz et al7 and Gantz et al.6
Abbreviations: DMT i, divalent metal transporter i; Gi, gastrointestinal; RBCs, red 
blood cells; Fe, iron.
Table 1 Comparative intravenous drip infusion regimens11–14,29
Product → iron sucrose Low-molecular- 
weight iron dextran
iron isomaltoside 1000 Ferric carboxymaltose Blood
Dose limitation 100 mg or 200 mg 100 mg or 200 mg 20 mg/kg body weight  
to total body weight
15 mg/kg up to  
max 1000 mg
None
Rate of administration 100 mg in 37.5 mins 
200 mg in 67.5 mins
100 mg in 37.5 mins 
200 mg in 41.25 mins
0–5 mg/kg body weight 
in 15 mins 6–10 mg/kg 
body weight in 30 mins 
11–20 mg/kg body  
weight in 60 mins
100 mg–200 mg no 
minimum time quoted 
200 mg–500 mg 6 mins
i unit 
(equ. 200 mg 
iron) 90 mins
Test dose Required for 
first administration
Required at each 
administration
Not required Not required N/ATherapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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patient status, ie, ambulatory or nonambulatory) and nursing 
costs (salary band 6 and 7). This was undertaken to provide 
a degree of robustness for the estimations. Analysis in the 
community was beyond the scope of this analysis because 
cost data were lacking to perform a comparative analysis 
(eg, rent).
Parameters for the cost model
standard treatment comparators
Standard treatment will vary according to local practice and 
indication. Traditionally, prior to the introduction of intra-
venous iron, blood (units of packed red blood cells) would 
have been the sole option in most of the indications/situa-
tions described earlier. Iron supplementation is increasingly 
used as an alternative. Intravenous iron is now used almost 
exclusively in hemodialysis patients, whereas in other situa-
tions, intravenous iron is progressively replacing the practice 
of administering a blood transfusion.
Given the European legislation in pursuit of reducing 
the risk associated with blood use and the appropriate use of 
blood, and in recognition that intravenous iron can provide 
a viable alternative, blood is included as a comparator.15,16 
Iron sucrose and low-molecular-weight iron dextran are also 
used as comparators.
Dose levels
The comparator doses have been chosen to reflect clinical 
practice. Blood is transfused in multiples of “units”. Each unit 
may be considered to approximate to 200 mg of iron.
Iron doses are commonly estimated using the Ganzoni 
formula that reflects body weight, the difference between 
actual hemoglobin level and target hemoglobin level, and 
the desired level of iron stores (commonly 500 mg).17 It is 
not uncommon for an individual’s requirement to be up to 
2000 mg across the range of conditions associated with 
anemia.18–22 Limitations of the previously available intrave-
nous iron supplements include the number and frequency 
of doses needed to achieve high level repletion when using 
iron sucrose and duration of administration for low-molec-
ular-weight iron dextran.
For the purposes of the cost minimization modeling 
three levels of administration have been chosen (to provide a 
dose sensitivity matrix), ie, 600 mg, 1000 mg, and 1600 mg. 
These allow direct comparison with units of blood (multiples 
of units each equivalent to 200 mg of elemental iron). The 
profiles of the two products, which have recently entered 
the market, allow high-dose use. The various doses have 
been constructed in a matrix that reflects cost assumptions 
appropriate for the range of doses.
Bioavailability and efficacy
In preparing this model, it was assumed that each of the 
intravenous iron preparations impact erythropoiesis and 
enter iron stores in a similar manner directly related to the 
dose administered. Whilst during the acute administra-
tion phase there may be differences in pharmacokinetic 
properties (such as differences in binding to the glucose 
moiety and rates of release of free iron) leading to potential 
Table 3 Comparative high-dose infusion regimens11–14
Product → iron sucrose Low-molecular- 
weight iron dextran
iron isomaltoside 1000 Ferric carboxymaltose Blood
Dose limitation 200 mg/administration 20 mg/kg 20 mg/kg 15 mg/kg max 1000 mg N/A
Rate of administration N/A* 20 mg/kg first 25 mg  
(test dose) over  
15 mins then balance  
to 45–60 drops/min
0–10 mg/kg in 30 mins 
11–20 mg/kg in 60 mins
,500 mg in 6 mins  
500–1000 mg 
in 15 mins
N/A
Test dose N/A Required at each 
administration
Not required Not required N/A
Note: *NB requires multiple administrations of 200 mg intravenous injections to deliver total dose.
Abbreviation: N/A, not applicable.
Table 2 Comparative intravenous bolus injection regimens11–14
Product → iron sucrose Low-molecular- 
weight iron dextran
iron isomaltoside 1000 Ferric carboxymaltose Blood
Dose limitation 100 mg or 200 mg 100 mg or 200 mg 100–200 mg Up to 200 mg N/A
Rate of administration 100 mg in 20 mins 
200 mg in 25 mins
100 mg in 25 mins 
200 mg in 35 mins
2–4 mins By injection (push) N/A
Test dose Required for 
first administration
Required at each 
administration
Not required Not required N/ATherapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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activation of oxidative stress processes, there is no evidence 
to   suggest that incorporation of iron into reticulocytes, 
elevation of hemoglobin levels, and development of iron 
stores will differ.23–27
The administration of intravenous iron differs physi-
ologically to the administration of a blood transfusion. 
Blood results in an immediate rise in hemoglobin level. This 
will decline as the erythrocytes die (average life 120 days 
in patients with normal renal function). Iron from a blood 
transfusion is then recycled as the erythrocytes expire. Blood 
has traditionally been used to treat iron deficiency anemia 
and may still be regarded as “standard treatment”.
Adverse events
In the cost modeling, no allowance is made for occurrence 
of adverse events. These are infrequent and similar for 
iron sucrose and low-molecular-weight iron dextran.11,12,28 
The summaries of product characteristics for iron isomalto-
side 1000 and ferric carboxymaltose indicate that adverse 
events associated with their use will be similar to those of 
currently available intravenous iron formulations.11–14
Blood has higher levels of risk, both as a product per se 
and from the potential human error associated with compat-
ibility testing and administration. Intravenous iron can be 
used universally (irrespective of blood type), has very limited 
contraindications, has a good shelf-life, and does not need 
controlled refrigerated storage conditions.
Dose and rate of administration limitations
In the cost modeling, sensitivity to the dose and rate of 
administration of the various products were considered. The 
following information (as per the relevant manufacturers’ 
summary of product characteristics), eg, rate of delivery and 
maximum dose, was included.
The manufacturers’ instructions for undertaking a test 
dose reflect whether the patient is receiving the medica-
tion for the first or subsequent time. For low-molecular-
weight iron dextran, if administering for the first time, a 
25-mg dose is administered and the patient observed for 
45 minutes.11 The balance can be administered if there are 
no adverse events. For the second and subsequent infu-
sions, the first 25 mg of iron is infused over 15 minutes 
and, if there are no untoward events, the administration 
can be continued.11 When a total dose is administered, 
the patient should be observed for a further hour after the 
completion of the administration.11 For the administration 
of iron sucrose, a test dose is required only for the first 
administration to a patient.12
For the purposes of this study, it was assumed that this 
was the second (or subsequent) administration to a patient of 
iron sucrose and low-molecular-weight iron dextran. For the 
specified range of doses, an observation period was included 
in the administration times for low-molecular-weight iron 
dextran (as indicated in the manufacturer’s summary of 
product characteristics).11 Given the recommended dilution 
volume for preparing the infusion, it was assumed that the 
administration plus observation period would be similar 
at each dose level, ie, six hours in total. In this analysis, 
10 minutes was allowed for infusion setup time across the 
range of preparations.
Transportation
This is an important factor when considering intravenous 
iron supplementation. Historically patients with chronic 
kidney disease (and chronic anemia) requiring dialysis 
would arrive at hospital on a stretcher or in a wheelchair. 
The availability of intravenous iron and erythropoiesis-
stimulating agents directly affects energy and ambulatory 
capability in many individuals. Across the spectrum of 
patients with iron deficiency anemia, a proportion will be 
short of breath, perhaps with palpitations, will invariably 
be nonambulatory, and will be transported to hospital on a 
stretcher or in a wheelchair.
In the UK, ambulance services are paid by the NHS (the 
public health service economy). For the purposes of this study, 
two types of “transported” patient are   considered, ie, those 
who are ambulatory, where the charge is £12.00/single 
  journey (£24.00 return) and those who are in a wheelchair or 
who require a stretcher where the charge for a single journey 
is £48.00 single (£96.00 return).30
Across the spectrum of causes of iron deficiency anemia, 
it is difficult to establish specifically the proportion of patients 
that require transportation and the ratio between ambulatory 
and nonambulatory for those who are anemic. It is realized 
that a proportion of patients will use self transport (or that of a 
friend or relative). For the purposes of this study, we have used 
a sensitivity matrix at two levels for the patient   population 
that require transport, ie, 10% and 20%. It is assumed that 
those requiring transport will be equally split between those 
who are ambulatory and those who are nonambulatory and 
who require a stretcher or wheelchair. The costs used were 
£24.00 per return journey for ambulatory patients and £96.00 
per return journey for nonambulatory patients.
The transport costs were taken from a report from the 
Doncaster and Bassetlaw Hospitals NHS Foundation Trust 
which indicated £48.00/journey (stretcher/wheelchair) and Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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£12.00 for ambulatory patients using an ambulance in 2007.30 
The Personal Social Services Research Unit (Unit Costs of 
Health, University of Kent) quoted the cost as £54.00 per 
urban patient journey in 2008.31 The lower costing has been 
used in this analysis.
Giving sets, cannula, and dressing
The cost of consumables varies across hospital establishments 
but, for the purpose of this analysis, unit costs reported by 
Bhandari and Naudeer32 were used. These were £7.89 for a 
“giving set”; £0.74 for one cannula, and £0.54 for a standard 
dressing.
Nursing time
In the nonrenal setting, it is probable that an anemia nurse 
will attend to patients either in a specialist clinic or medical 
diagnostic unit. Nursing costs have been estimated using 
the hourly costs associated with a band 6 and band 7 nurse, 
using the midband range increment. The costs were taken 
from the Personal Social Services Research Unit and are 
appropriate for a ‘nurse led’ clinical service.33 The costs 
for one hour of ‘patient contact’ nursing time in the UK at 
midband 6 and 7 are £67.00 and £77.00, respectively. In 
the cost allocations, assumptions were made with regard to 
allocating time to represent multitasking (ie, not dedicating 
sole time to an individual patient during a six-hour low-
molecular-weight iron dextran total dose infusion). Thus, 
for a short (approximately 30-minute) administration time, 
a nurse is likely to attend for the   duration. For an infusion 
taking about 60 minutes, it is assumed that the nurse will 
spend 50% of his/her time with the patient, whereas for a 
prolonged infusion of low-molecular-weight iron dextran, a 
nurse is considered to spend 33% of his/her time with the 
patient (during the test dose phase and observation phase 
this may be 100%). This sensitivity has been used for both a 
band 6 and band 7 nurse.
Cost of intravenous iron products
Prices were taken from the British National Formulary or 
from the manufacturer. For 200 mg iron, these were £17.00 
for iron sucrose,34 £15.94 for low-molecular-weight iron 
dextran,34 £43.50 for ferric carboxymaltose,34 and £33.90 for 
iron isomaltoside 1000.35
Cost of blood
In some countries blood is not charged either to the patient, 
the providing institution or hospital, or payer. However, 
there is a cost to the health care economy and, as such, is 
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600 mg and 1000 mg across all sensitivity parameters 
(Tables 4, 5 and 6).
Discussion
Blood continues to be used to treat iron deficiency anemia, 
in the absence of acute blood loss, in a number of   conditions. 
NHS Blood and Transplant have established policies to 
reduce blood use, which includes the use of intravenous iron 
as an alternative to blood.2 Intravenous iron is used to treat 
iron deficiency anemia in many clinical situations and in an 
increasing number of specialties. In a cost- and time-effective 
health care environment, it is appropriate to examine the rela-
tive costs of administering newly introduced treatments and 
compare these with existing interventions. This is particularly 
relevant to the use of intravenous iron as an alternative to 
a blood transfusion.
Renal medicine has been at the forefront of pioneering 
the use of intravenous iron, initially in hemodialysis patients, 
resulting in a dramatic reduction in the requirement for blood 
transfusions. This practice has largely reflected the availabil-
ity of iron sucrose. Iron sucrose can be administered in doses 
up to 200 mg in a single administration and, as such, it was 
adopted in hemodialysis units and given to patients during 
one of their weekly hemodialysis sessions.
The use of iron to address iron deficiency anemia associ-
ated with chronic kidney disease stages 1–4 has now extended 
to low clearance (predialysis, Stage 5 nondialysis) patients and 
patients undergoing continuous ambulatory peritoneal dialy-
sis. These patients attend their renal units only   occasionally. 
To achieve iron adequacy, to replete stores, and meet eryth-
ropoietic needs (functional and absolute), large doses of 
intravenous iron are administered on a low frequency basis 
(normally every 3–12 months), and hence the need for the 
ability to administer total repletion doses. This can be achieved 
by administering multiple doses of 200 mg (iron sucrose) or 
from a total repletion dose of iron at a single visit. Note that 
chronic kidney disease patients in the nondialysis (Stage 5) 
stage of disease progression and those undergoing continuous 
ambulatory peritoneal dialysis are unlike the hemodialysis 
patients who attend clinic two or three times each week for 
dialysis, and who normally receive small doses of iron weekly 
or every two weeks   during a dialysis session.
In a few renal units in the UK, the rate of administration 
of low-molecular-weight iron dextran has been accelerated 
with the aim of reducing infusion times and improving 
  productivity (patient throughput).32,37 This practice is outside 
of the administration procedure stated in the manufacturer’s 
summary of product characteristics and is not standard 
appropriate for its costs to be included as a comparator. The 
costs used in this modeling are those charged in England and 
Wales to NHS hospitals for 2009/10 and are £133.51/unit 
for red blood cells, not including the cost of pretransfusion 
cross-matching of the patient’s blood and error checking.36 
This cost is difficult to find or calculate and, in the context 
of the cost of blood per se, this does not have a major affect 
on the final analysis. The time for administration of a blood 
transfusion (one unit) is at least 90 minutes (and up to 180 
minutes), except in a situation of major hemorrhage.29
Other costs considered minor or unlikely to be significant 
to the outcomes were excluded. This can be justified on the 
basis that, in any particular unit, the practice is likely to have 
a similar impact across the intravenous iron options. A cost 
deliberately omitted was that of the clinician. Whilst likely to 
be available during a transfusion, he/she would be undertak-
ing other clinical/administrative duties, whilst a nurse would 
normally be responsible for administering the infusion and 
managing/monitoring the procedure. An example of a minor 
cost is that of the infusion fluid (normal saline) which costs 
£0.70 per 250 mL.32
Results
A matrix was prepared to compare the full cost of admin-
istration of the three different dose levels of intravenous 
iron (as may be required for treating iron deficiency anemia 
in Stage 5 chronic kidney disease patients or patients with 
any of the other conditions associated with iron deficiency 
anemia). From these cost minimization models, at each 
dose level, the cost of administering iron isomaltoside 1000 
is the lowest cost option when compared with what may be 
considered standard treatments, ie, blood or iron sucrose. 
Iron isomaltoside 1000 is less expensive than both at doses 
of 600 mg, 1000 mg, and 1600 mg.
Compared with ferric carboxymaltose, the cost of 
administering iron parenterally at the three dose levels is 
again achieved at a comparatively lower cost when using 
iron isomaltoside 1000 at each dose level and at each level 
of sensitivity (nurse grade and patient transportation). As the 
dose of iron administered increases, the actual and percentage 
saving from using iron isomaltoside 1000 compared with 
ferric carboxymaltose increases.
Iron isomaltoside 1000 offers cost advantages compared 
with using blood, iron sucrose, and ferric carboxymaltose 
in each of the matrices at the three dose levels. When 
compared with low-molecular-weight iron dextran, iron 
isomaltoside 1000 is more expensive at the 1600 mg dose 
level. However, it is cost beneficial at the dose levels of Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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procedure, but illustrates the clinical need and desire to be 
able to give total doses of intravenous iron more rapidly.
The results of this cost minimization modeling (Tables 4, 5 and 
6) indicate that iron isomaltoside 1000 offers cost savings at 
three dose levels, across a range of sensitivities, when compared 
with blood and iron sucrose, which are considered to be the 
current standard of care. Likewise, across the same dose ranges, 
iron isomaltoside 1000, the most recent introduction, offers 
savings when compared with ferric carboxymaltose.
The findings with regard to the comparative costs 
associated with low-molecular-weight iron dextran are 
less equivocal, in that using the 1600 mg dose model, the 
outcome slightly favors low-molecular-weight iron dextran 
(Table 6). At the 1600 mg level, the maximum additional 
cost if using iron isomaltoside 1000 compared with low-
molecular-weight iron dextran would be £45.04 (13.8%). 
This suggests that low-molecular-weight iron dextran could 
be considered, based solely on cost, for patients receiving 
a dose of 1600 mg. However, in the modeling, no account 
or value is placed on inconvenience to the patient (time in 
clinic) or the opportunity cost of throughput by occupying 
a bed or treatment chair for over six hours. Such modeling 
looks at variable costs and does not allocate overhead costs 
or consider unit throughput efficiency. This has implications 
in the payment by results system.
The key cost drivers are cost of medication, time to 
administer (affecting nurse resource), and transportation. 
The cost of the various iron formulations are NHS acqui-
sition prices. Nursing costs have been calculated at two 
grade   levels. Additional assumptions relate to time spent 
with patients during administration. This will be further 
affected by location of administration (eg, ward, medical 
investigations unit, hematology day unit). Observation and 
consultation resulted in allocating 12.5% of a nurse’s time to 
a blood transfusion; 33% of the time was allocated to a patient 
receiving low-molecular-weight iron dextran and 50% to a 
patient being administered iron isomaltoside 1000 (at doses 
of 1000 mg and 1600 mg). At the 600 mg dose level, the 
administration can be undertaken in 30 minutes for a patient 
over 60 kg in body weight, so a nurse will spend his or her 
full time with the patient.
With regard to transportation, the frequency and type 
needed will reflect a number of factors, including underly-
ing causative condition, age, comorbidities, disabilities, 
mental capability, social support network, and urban versus 
rural domicile. To reflect this, transport was assumed to be 
necessary for 10% and 20% of the population and, at each 
level, half were ambulatory and half were   nonambulatory. 
The costs used were £12.00/ambulatory patient and 
£48.00/  nonambulatory patient for a single journey. This is 
  considerably below the Personal Social Services Research 
Unit cost of patient journeys which, if used, would have 
increased the cost of treatments requiring more than one 
visit (iron sucrose and ferric carboxymaltose at the 1600 mg 
dose level).
The ability to administer high doses of intravenous iron 
rapidly, without the need for a test dose, is an important 
development in the strategy to reduce the use of blood, to 
improve the treatment, and avoid iron deficiency anemia. 
Ferric carboxymaltose, was the first intravenous iron to be 
introduced to the UK which did not require a test dose. Whilst 
it can be given rapidly, it can be administered at a maximum 
of 15 mg/kg body weight and to a ceiling of 1000 mg per 
infusion, limited to once a week. Iron isomaltoside 1000, 
whilst also administered rapidly, allows for 20 mg of iron 
per kg of body weight. This range of dosing offers a broader 
spectrum of treatment, including total dose infusions, for 
a potentially larger proportion of patients. This may be of 
particular importance when calculating the treatment dose 
based on the Ganzoni formula that includes replenishing body 
iron stores.17 Doses for a number of disorders associated with 
iron deficiency anemia commonly require doses in excess of 
1000 mg.18–22 Patients requiring more than 1000 mg of iron 
will require more than one infusion of ferric carboxymaltose, 
necessitating two or more hospital or clinic visits.
Conclusion
Parenteral iron treatment has advanced significantly. Initially, fer-
ric carboxymaltose offered the option of high-dose intravenous 
iron that could be administered in a short time span, and does 
not require a test dose, but is limited to 15 mg/kg body weight 
up to a maximum of 1000 mg in a single administration. This 
has been followed by the introduction of iron isomaltoside 1000 
which likewise does not require a test dose, can be given rapidly, 
and offers the scope of dosing at up to 20 mg/kg body weight.
In a cost-conscious health care environment, the relative 
holistic cost of administering these new formulations has to 
be considered when making prescribing policy decisions. 
This cost minimization study indicates that savings can 
accrue by adopting iron isomaltoside 1000 when compared 
with current standard practice (iron sucrose or blood) at three 
dose levels. It is less expensive than using ferric carboxy-
maltose at the three dose levels, ie, 600 mg, 1000 mg, and 
1600 mg. Whilst in the modeling, low-molecular-weight iron 
dextran is marginally cheaper to administer at the 1600 mg 
dose level (but not at the 600 mg or 1000 mg levels), the Therapeutics and Clinical Risk Management 2011:7
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time to administer this formulation takes six hours, thereby 
restricting patient throughput and the number of patients 
treated, and affecting unit efficiency. Low-molecular-weight 
iron dextran is also less convenient for patients.
It is acknowledged that there are limitations to the analy-
sis, as detailed in the discussion. Such an analysis cannot be 
absolutely comprehensive in considering all costs applicable 
in all units. These are dependent on the availability of alter-
native preparations to a unit to choose from, desired clinical 
outcomes (eg, target hemoglobin and ferritin levels) and 
facilities. Clearly, staff time and transportation are important 
dynamics in the context of a comprehensive cost analysis, but 
are often omitted, resulting in the unit cost of the medication 
becoming the sole factor for decision-making.
This analysis suggests that iron isomaltoside 1000 is a 
convenient and more cost-effective intravenous iron treatment 
for iron deficiency anemia than the current most widely pre-
scribed intravenous iron, ie, iron sucrose, or a blood transfu-
sion in clinical situations where high-dose iron repletion is 
clinically appropriate. This may be particularly important in 
the strategy of reducing blood use and reducing the incidence 
and volume of blood transfusions in the UK.
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